Review anchor
Macrophage-stimulating protein receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Macrophage-stimulating protein receptor
CHEMBL2689
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Macrophage-stimulating protein receptor as ChEMBL target CHEMBL2689, mapped to UniProt Q04912. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2689
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q04912
Macrophage-stimulating protein receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Macrophage-stimulating protein receptor matters
Macrophage-stimulating protein receptor is reviewed as Macrophage-stimulating protein receptor (UniProt Q04912); Macrophage-stimulating protein receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 1676 compounds, and 378 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Macrophage-stimulating protein receptor
Macrophage-stimulating protein receptor Sequence length is 1400 aa.
Review this target as Macrophage-stimulating protein receptor, mapped to UniProt Q04912. Sequence length is 1400 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q04912
Protein
Disease context
cancer
Macrophage-stimulating protein receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CRIZOTINIB, GLESATINIB, MK-8033.
Start review with cancer because it currently carries approved-linked support. Linked drugs include CRIZOTINIB, GLESATINIB, MK-8033, NARNATUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 13 approved drugs, 1676 compounds, and 378 assays for this target. The dominant activity type is KI. CHEMBL5430218 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL5430218 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
13 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Macrophage-stimulating protein receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q04912, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1676
Total Compounds
378
Total Assays
13
Approved Drugs
IC50: 256.0, KI: 337.0, EC50: 2.0, KD: 325.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5430218
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL1980995
|
9.6 | Ki | — |
|
|
No preferred name
CHEMBL5427445
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL5419134
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL5396164
|
9.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
GILTERITINIB
CHEMBL3301622
|
2018 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
Source Header